Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

44 clinical studies listed.

Filters:

Neoplasm Metastasis

Tundra lists 44 Neoplasm Metastasis clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07697989

Pluvicto Real-world Investigation in Survival in Metastatic CRPC

This study aims to evaluate the various aspects of treatment effectiveness of \[177Lu\]Lu-PSMA-617 (Pluvicto) in mCRPC patients in both pre- and post-taxane settings. The study will be conducted using real-world data sources from the United States (US) and Germany.

Gender: MALE

Ages: 18 Years - 100 Years

Updated: 2026-11-20

1 state

Prostatic Neoplasms, Castration-Resistant
Neoplasm Metastasis
NOT YET RECRUITING

NCT07946393

Preoperative CA 19-9 and the Pattern and Timing of Recurrence After Pancreatoduodenectomy (Whipple Operation) for Pancreatic Cancer

Surgery to remove the head of the pancreas (pancreatoduodenectomy, also called the Whipple operation), usually followed by chemotherapy, is the only treatment that offers long-term survival for cancer in the head of the pancreas (pancreatic ductal adenocarcinoma). Even so, the cancer comes back (recurs) in most patients. Where it comes back first (around the operation site, in the liver, in the lining of the abdomen, in the lungs or elsewhere) and how soon it comes back both affect survival, the choice of further treatment and how patients should be followed up. CA 19-9 is a blood test measured routinely before this operation. A high level is known to be linked with shorter survival, but whether it also predicts where and when the cancer will recur is uncertain and, to the investigator's knowledge, has not been studied in patients treated in Egypt. Jaundice, which is common in these patients, can raise CA 19-9 falsely, so this study uses only CA 19-9 values measured when the blood bilirubin level was close to normal (2 mg/dL or less). This is a retrospective study of existing medical records. It includes adults who had a Whipple operation for this cancer at the Hepatopancreatobiliary and Surgical Oncology Unit, Liver and GIT Hospital, Minia University, Egypt, between January 2017 and December 2024, with follow-up information from Minia Oncology Centre. No patient will receive any test or treatment for the study, and no care will be changed. Patients will be compared according to their preoperative CA 19-9 level (37 U/mL or less versus more than 37 U/mL). The two main questions are whether the preoperative CA 19-9 level is linked to (1) the site of the first recurrence and (2) the time from surgery to recurrence. A recurrence will count only when confirmed by scans or biopsy, never by a rising CA 19-9 alone, and it will be classified by independent doctors who do not know the patients' CA 19-9 results. Other questions include recurrence within 6 and 12 months of surgery, survival, and whether CA 19-9 adds useful information to the routine findings available before surgery. The investigator expects that patients with a high CA 19-9 will more often recur first in the liver or the lining of the abdomen and will recur sooner, whereas patients with a normal level will recur later and more often only near the operation site. The findings may help tailor follow-up after surgery, identify patients who might benefit from chemotherapy before surgery, and identify patients whose cancer is likely to come back only at the operation site, who might be considered for further local treatment.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-18

1 state

Pancreatic Ductal Adenocarcinoma
Pancreatic Neoplasms
Neoplasm Recurrence, Local
+1
RECRUITING

NCT07944235

Preoperative and Postoperative Radiosurgery in Patients With Brain Metastases Undergoing Surgery

The PREOP-RAD study aims to evaluate the feasibility, safety, and efficacy of preoperative surgical resection (SRS) in patients with large brain metastases requiring surgical resection, taking into account potential differences based on sex/gender, compared to postoperative SRS, within the Spanish healthcare context. More specifically, the study seeks to: * Assess the clinical and radiological outcomes of the preoperative strategy in terms of local control, progression-free survival, and the occurrence of radionecrosis or neuromuscular dysfunction (nMD) compared to the postoperative strategy. * Study the histopathological profile of resected lesions before and after SRS, searching for personalized biomarkers of response and toxicity. * Identify patterns based on radiomic analysis and advanced imaging related to therapeutic response, recurrence, and complications. PREOP-RAD is a prospective, randomized, multicenter study that will include patients diagnosed with symptomatic, single or multiple brain metastases ≥2 cm who are candidates for surgical resection. The procedure will consist of preoperative administration of SRS (1-5 fractions, depending on location and size), followed by surgery within a maximum of 10 days. The intervention will be carried out in coordination with the Neurosurgery and Radiation Oncology Departments of each participating center, using a standardized workflow. The collection of surgical samples will allow for centralized histopathological studies. Furthermore, pre- and postoperative images will undergo radiomic analysis using artificial intelligence tools to explore similarities and correlate morphological and textural characteristics with clinical outcomes.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-18

4 states

Brain Neoplasms
Neoplasm Metastasis
Radiosurgery
+3
NOT YET RECRUITING

NCT07944144

A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to learn about the safety of a new medicine called IPN60350 and how the body responds to it. Researchers will also look for early signs of antitumor activity in adults with locally advanced or metastatic solid tumors. All participants in this study will receive IPN60350, either alone or in combination with other anticancer therapies. The study has two parts. * Phase Ia (dose escalation) will test IPN60350 at different dose levels to learn which doses are safe and can be given in future parts of the study. * Phase Ib (dose optimization and expansion) will test one or more selected dose levels in a larger number of participants. This will help researchers better understand the safety of IPN60350 and whether it shows early signs of antitumor activity in different tumor types. Each part will consist of the following periods: * A screening period (up to 28 days) to assess whether the participant can take part, requiring at least 1 visit to the study center. * A treatment period where IPN60350 is administered in repeating treatment cycles. The study includes health assessments, blood tests, tissue samples (biopsies), and imaging scans to help researchers better understand the safety of IPN60350 and its potential effects on tumors.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-18

Neoplasms
Neoplasm Metastasis
Neoplastic Processes
+1
RECRUITING

NCT04886804

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

The study has 2 parts. The first part is open to adults with different types of advanced cancer (solid tumours with changes in the HER2 gene) for whom previous treatment was not successful. The second part is open to people with non-small cell lung cancer with a specific mutation in the HER2 gene. The purpose of the first study part is to find the highest dose of a medicine called zongertinib the participants can tolerate. Once this dose is found, it will be used in the second study part to test whether zongertinib can make tumours shrink. In this study, zongertinib is given to people for the first time. Participants take zongertinib as tablets once a day or twice a day. The participants are in the study for as long as they benefit from and can tolerate treatment. Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by zongertinib.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-12

14 states

Neoplasm Metastasis
Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING

NCT07046923

A Study of LY4175408 in Participants With Advanced Cancer

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-12

13 states

Carcinoma, Non-Small-Cell Lung
Small Cell Lung Carcinoma
Endometrial Neoplasms
+2
NOT YET RECRUITING

NCT07928362

A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer

This study is a multicenter, prospective, single-arm, open-label, Simon two-stage phase II clinical trial designed to evaluate the conversion therapeutic value of multimodal thermal therapy combined with TIS (Toripalimab) and AG chemotherapy (gemcitabine plus nab-paclitaxel) in previously untreated metastatic pancreatic cancer patients with liver-only or lung-only metastases.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-11-10

4 states

Pancreatic Neoplasms
Neoplasm Metastasis
RECRUITING

NCT05614739

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-04

21 states

Urinary Bladder Neoplasms
Neoplasm Metastasis
Ureteral Neoplasms
RECRUITING

NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-04

37 states

Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
RECRUITING

NCT07114601

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive advanced cancer, including but not limited to breast, colorectal, prostate, endometrial, esophageal, gastroesophageal (GE) junction, and gastric cancer. The study will also evaluate the safety, tolerability, and efficacy of LY4257529 to identify cancer with high levels of a protein called GRPR. This is a 2-part study. Participation could last up to 36 weeks or until your tumor progresses.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-04

9 states

Breast Neoplasms
Colorectal Neoplasms
Prostate Neoplasm
+4
RECRUITING

NCT07174336

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-04

39 states

Breast Neoplasms
Neoplasm Metastasis
RECRUITING

NCT07213804

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with platinum-resistant cancer, meaning their disease progressed during or within six months of platinum-based chemotherapy. Parts B and C enroll participants with platinum-sensitive cancer, whose disease responded and remained controlled for at least six months after completing platinum treatment. The researchers want to find out if Sofe-M works better than the standard treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.

Gender: All

Ages: 18 Years - Any

Updated: 2026-11-04

33 states

Ovarian Neoplasms
Fallopian Tube Neoplasms
Peritoneal Neoplasms
+1
NOT YET RECRUITING

NCT07904013

Impact of a Radiologic and Immunologic Signature on Cerebral Efficacy of Treatments in Lung Cancers With Brain Metastasis

Non-small cell lung cancer frequently spreads to the brain, and brain metastases are associated with poor prognosis and limited treatment response. This retrospective study will investigate whether quantitative features extracted from brain magnetic resonance imaging (MRI), known as radiomic features, are associated with the immune characteristics of brain metastases assessed by bulk RNA sequencing. The main objective is to identify relationships between MRI-based radiomic signatures and tumor immune profiles. A secondary objective is to determine whether radiomic, transcriptomic, or combined radio-transcriptomic signatures can help predict cerebral progression during immunotherapy. The study hypothesis is that MRI-based radiomic signatures may reflect the immune environment of brain metastases and could provide a non-invasive approach for predicting treatment response.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-29

Carcinoma
Non-Small-Cell Lung
Brain Neoplasms
+1
COMPLETED

NCT05103358

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Gender: All

Ages: 12 Years - Any

Updated: 2026-10-28

34 states

Tumor
Tumor, Solid
Metastasis
+18
ACTIVE NOT RECRUITING

NCT05440786

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.

Gender: All

Ages: 1 Year - 39 Years

Updated: 2026-10-20

17 states

Sarcoma, Ewing
Neoplasm Metastasis
RECRUITING

NCT07218380

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-07

27 states

Carcinoma, Transitional Cell
Urinary Bladder Neoplasms
Neoplasm Metastasis
ACTIVE NOT RECRUITING

NCT05169567

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.

Gender: All

Ages: 18 Years - Any

Updated: 2026-10-06

69 states

Breast Neoplasm
Neoplasm Metastasis
NOT YET RECRUITING

NCT07824856

Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma

This single-center, open-label, randomized phase II trial evaluates whether CT-guided local ablation of liver and/or lung oligometastases, added to systemic therapy, improves the objective response rate compared with systemic therapy alone in patients with metachronous liver and/or lung oligometastases (no more than 5 lesions, each 3 cm or smaller) from nasopharyngeal carcinoma.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2026-09-17

1 state

Nasopharyngeal Carcinoma
Neoplasm Metastasis
Lung Metastases
+3
RECRUITING

NCT05573893

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

This is a prospective non-interventional, multicenter study observing patient reported outcomes as well as real-world efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with documented Human epidermal growth factor receptor 2 (HER2)-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer (BC) receiving T-DXd in line with the applicable summary of product characteristics (SmPC) within routine clinical practice in Germany. In addition, patients will be informed about use of digital healthcare application (DiGA).

Gender: All

Ages: 18 Years - 130 Years

Updated: 2026-09-11

Breast Neoplasms
Breast Cancer
Neoplasm Metastasis
ACTIVE NOT RECRUITING

NCT00781612

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.

Gender: All

Ages: 18 Years - Any

Updated: 2026-08-28

47 states

Neoplasm Metastasis
COMPLETED

NCT06460961

A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not responded to conventional therapy. There will not be any hypothesis testing in the study. As of Amendment 04 (effective date: 18-Dec-2025), there are no pharmacokinetic (PK) secondary outcome measures in this study.

Gender: All

Ages: 18 Years - Any

Updated: 2026-08-28

6 states

Neoplasm Metastasis
ACTIVE NOT RECRUITING

NCT02892305

Hepatic Resection for Metastatic Pancreatic Cancer

The purpose of this study is to demonstrate the feasibility of an aggressive multimodal approach among patients with stage IV pancreatic cancer (PAC) with isolated, low-volume hepatic metastasis (LVHM). We will evaluate and describe the surgical and overall outcomes of an initial cohort of subjects who undergo pancreatectomy and hepatic resection/ablation for PAC with LVHM. The end of study results will be reviewed by the Hepatiobiliary Multidisciplinary Conference (HDMC) and Surgery Audit Committee (SAC) to determine the appropriateness of adding this treatment arm for patients with oligometastatic metastatic pancreatic cancer.

Gender: All

Ages: 18 Years - 90 Years

Updated: 2026-08-27

1 state

Pancreatic Neoplasms
Neoplasm Metastasis
Liver Metastases
NOT YET RECRUITING

NCT07151586

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

This is a phase II, multicentre, open-label, randomised controlled trial (patients are randomly assigned to one treatment arm or the other) evaluating two treatment strategies (sacituzumab govitecan and trastuzumab deruxtecan in an alternative schema or sacituzumab govitecan alone) in patients with locally advanced or metastatic triple-negative breast cancer. The goal is to answer the question: Does alternating sacituzumab goveitecan (SG) and trastuzumab deruxtecan (T-DXd) improve survival in patients with HER2-low metastatic triple-negative breast cancer compared to continuing treatment with SG alone?

Gender: All

Ages: 18 Years - Any

Updated: 2026-08-03

Triple Negative Breast Neoplasms
Neoplasm Metastasis
HER 2 Low-expressing Breast Cancer
ACTIVE NOT RECRUITING

NCT04975308

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.

Gender: All

Ages: 18 Years - Any

Updated: 2026-07-22

124 states

Breast Neoplasms
Neoplasm Metastasis